Literature DB >> 12108180

[Liveoid vasculopathy with combined thrombophilia: efficacy of iloprost].

N Magy1, M P Algros, E Racadot, H Gil, B Kantelip, J L Dupond.   

Abstract

INTRODUCTION: Livedoid vasculopathy is characterized by early, focal painful purpuric lesions of the lower skin extremities without histologic finding of small vessel vasculitis. EXEGESIS: A 38-year-old man was seen in our unit for painful purpuric lesions of both feet localized on toes and external sides. Skin biopsy showed dermic vessel thrombosis and endothelial cell proliferation. Lupus anticogulant antibody was positive in association with a heterozygous factor V (Leiden) gene mutation (G1691A). Anticoagulation failed to relieve pain and cutaneous lesions. Intravenous iloprost, a prostacylcin analogous (Ilomedine) was dramatically and rapidly effective in our patient.
CONCLUSION: Livedoid vasculopathy is a cutaneous affection related to vascular thrombotic events in which thrombophilia plays a central role. Iloprost might be an interesting alternative treatment of painful purpuric lesions when anticoagulant treatments are ineffective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12108180     DOI: 10.1016/s0248-8663(02)00611-2

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  3 in total

1.  Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

Authors:  Noha A Irani-Hakime; Farid Stephan; Raghid Kreidy; Isabelle Jureidini; Wassim Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2008-03-23       Impact factor: 2.300

2.  Ulcerative livedoid vasculopathy responding to clopidogrel.

Authors:  Elaine Kunzler; Benjamin F Chong
Journal:  JAAD Case Rep       Date:  2018-02-03

Review 3.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.